Comparative Pharmacology
Head-to-head clinical analysis: ALAMAST versus OPTICROM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALAMAST versus OPTICROM.
ALAMAST vs OPTICROM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mast cell stabilizer; inhibits release of histamine and other inflammatory mediators from mast cells.
Mast cell stabilizer; inhibits release of histamine and other inflammatory mediators from mast cells.
1 or 2 drops (0.025% or 0.05% solution) in each affected eye four times daily.
2 drops in each eye 4 times daily. Administration: ophthalmic topical.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in healthy adults; steady-state achieved within 2-3 days; prolonged in renal impairment.
Terminal elimination half-life is approximately 80-100 minutes in adults; clinically, this supports dosing every 4-6 hours for sustained effect.
Primarily renal excretion of unchanged drug (approximately 70-80% of dose); biliary/fecal elimination accounts for the remainder (20-30%).
Primarily excreted unchanged in urine (approximately 50-60%) and feces (approximately 40-50%) via biliary elimination.
Category C
Category C
Mast Cell Stabilizer (Ophthalmic)
Mast Cell Stabilizer (Ophthalmic)